From the publishers of JADPRO
Multiple Myeloma
Resource Center
Menu
Resources
Videos
Videos
Quizzes
News & Literature Highlights
Case Studies
Advertisement
Test your knowledge in a multiply relapsed multiple myeloma case
Last Updated: Wednesday, February 28, 2024
A Heavily Treated Relapsed/Refractory Multiple Myeloma Patient on Talquetamab
Loading...
Advertisement
News & Literature Highlights
JCO Precision Oncology
Expanding the therapeutic reach of chimeric antigen receptor T-cells and bispecific T-cell engagers across solid tumors
Open Forum Infectious Diseases
Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: A 7-year retrospective cohort study
Cancer Reports
Efficacy and safety of quadruplet therapy in newly diagnosed transplant-eligible multiple myeloma: A systematic review and meta-analysis
Clinical Lymphoma, Myeloma & Leukemia
Expert perspectives on current challenges and emerging approaches for multiple myeloma: Narrative review of an inaugural bridging the gaps in leukemia, lymphoma, and multiple myeloma
Cancer Medicine
Application of GPRC5D targeting therapy in relapsed refractory multiple myeloma
The Lancet Haematology
Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): A multicentre, open-label, phase 1-2 study
Mediterranean Journal of Hematology and Infectious Diseases
How first-line therapy is changing in non-transplant eligible multiple myeloma patients
Cancer Medicine
Treatment of multiple myeloma in patients refractory to daratumumab/anti-CD38 monoclonal antibodies: A systematic review
Iranian Journal of Medical Sciences
Advancing multiple myeloma immunotherapy: A review of chimeric antigen receptor T-cell and bispecific T-cell engagers cell therapies in revolutionizing treatment
European Journal of Haematology
Completion of distress screening and correlates of distress score in patients with multiple myeloma at initial evaluation at a transplant center
Advertisement
Case Studies
Treatment of Intermediate Risk Smoldering Myeloma
Patient Newly Diagnosed With MM and Ineligible for SCT With Relapse on Anti-CD38 and Lenalidomide-Based Therapy
Single Solitary Plasmacytoma to Active Myeloma
Advertisement
Quizzes
Test your knowledge on intermediate risk smoldering multiple myeloma
Test your knowledge on managing a patient newly diagnosed with MM and ineligible for stem-cell transplant
Test your knowledge of newly diagnosed multiple myeloma